Nybörjare
From Molecule to Platform: What the Abogen–Novartis Deal Means for mRNA Innovation
As mRNA therapeutics move into new disease areas, the next challenge is turning promising science into scalable, reproducible development process...
Phase 3 Victory for First Individualized mRNA Cancer Vaccine: What Solutions Are Needed for the New Era of mRNA Therapeutics?
On August 19, 2026, monumental news capable of entering the annals of oncology history arrived: Moderna and Merck jointly announced that the Phase ...
Cancer Cell (IF 44.5) | Tumor Cells Resist Immune Checkpoint Therapy via Macrophage Efferocytosis-Mediated Fatty Acid Recycling
Source: Liang Z, Long X, Wong PP, et al. Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid...
From Research to Regulatory Practice: Advancing NAT-Based Mycoplasma Testing for Biologics
Mycoplasma contamination remains one of the most persistent safety concerns throughout biologics manufacturing—from cell banking and viral vector ...
Fast, Accurate, and Reliable Molecular Diagnostic Solutions for Nipah Virus Surveillance
Urgent Alert: Nipah Virus Outbreak in India
A recent Nipah virus (NiV) outbreak in West Bengal, India has triggered emergency public health resp...
Exciting News! Yeasen’s GMP-Grade UltraAAV PEI Transfection Reagent Achieves FDA DMF Registration
Yeasen Biotechnology has officially received confirmation from the U.S. Food and Drug Administration (FDA): our UltraAAV PEI Transfection Reagent–G...
Synthesis of siRNA and the Role of T4 RNA Ligase 2
Small interfering RNA (siRNA) is a powerful tool in molecular biology, widely used for gene silencing through RNA interference (RNAi). These short,...
Yeasen Groundbreaking Milestone in High Temperature Bst DNA Polymerase Evolution for Eliminating False Positive Issues in LAMP Assays
Published in ACS Catalysis
Loop-mediated isothermal amplification (LAMP) is a powerful DNA amplification technique celebrated for its simplicity...
mRNA-teknikgenombrott: Yeasen avslöjar den låga toxiciteten och den höga översättningshemligheten för T7 RNA-polymerasmutanter
Engineered Enzyme reducerar skadliga dsRNA, banar väg för säkrare mRNA-terapi Forskare från Yeasen Biotechnology och dess dotterbolag Molefuture...
Integrerat nukleinsyrasystem för att producera ultralegen låg DNA-molekylära enzymer
Nukleinsyrakontamination har länge varit ett betydande hinder för utvecklingen av molekylär diagnostisk teknologi. I takt med att känsligare diagno...
Grattis! UCELLO: s sladdblod-härledda allogena universella CAR-T godkänd av US FDA IND!
Ucello Biotechnology Co., Ltd., en viktig strategisk partner till Yeasen Bioteknik, har självständigt utvecklat en CD19-riktad chimär antigenrecept...
Dela valideringsrapporten för det dubbelsträngade RNA (dsRNA) ELISA-kit för att främja standardiseringen av dsRNA-detektion.
Letar du efter ett tillförlitligt sätt att detektera kvarvarande dsRNA under mRNA in vitro-transkription? Leta inte längre än det dubbelsträngade R...